Background: Gastric cancer (GC) remains a refractory cancer worldwide. Currently, exploring the differences of the immune status in GC patients with different subgroups might provide promising immunotherapeutic approaches for the treatment of GC.
gastric adenocarcinoma into additional subtypes, which is widely used [6, 7] . Some studies have described poor prognosis for the signet ring cell carcinoma and mucinous adenocarcinoma compared with other subtypes of GC [8, 9] .
With GC progression, the infiltrating status of specific immune cells and their differences in predicting prognosis have not been discussed at length in different pathological classifications of GC. Given that GC is a complex disease with heterogeneity [10] , subgroup analysis is necessary to further improve the accuracy of immune indicators for the prognosis of GC patients.
Chemotherapy with platinum and fluoro-pyrimidine is currently the recommended first-line therapy for patients with advanced or metastatic GC who have good performance status [11] . In recent years, immunotherapy with immune checkpoint inhibitors has revolutionized the treatment of advanced cancer and demonstrated quite promising results [12] [13] [14] . Blockade of the PD-L1/PD-1 pathway remains ineffective in GC [15, 16] . Hence, to enhance the efficacy of immunotherapy in GC, identifying some more precise predictive biomarkers in order to select better GC patients who might benefit most from immunotherapy is urgently required. Recently, a positive correlation between the presence of tumor-infiltrating lymphocytes (TILs) and survival of patients with malignancies was reported [5] . High infiltration of CD3 + and CD8 + T lymphocytes is associated with better outcome in GC, demonstrating the critical role of T cell-mediated host immunity in repressing tumor progression [17, 18] . Tumor infiltrative forkhead box P3-positive (FOXP3 + ) regulatory T cells (Tregs) might play a crucial role in the immune microenvironment of GC [19] [20] [21] . However, the prognostic value of Treg infiltration remains controversial in GC patients [22, 23] . Also, tumor-associated macrophages (TAMs) are known to directly or indirectly support the tumor growth and metastasis in GC and are positively associated with the depth of invasion and clinical stage. TAMs display high plasticity and perform diverse, supportive functions which were specialized for different tissue compartments [24, 25] . M2 macrophages are associated with promoting tumor growth, remodeling tissue, promoting angiogenesis, and suppressing adaptive immunity. CD163, a member of the scavenger receptor cysteine-rich family, is a M2 macrophage marker [26, 27] .
In this study, we used a tissue microarray (TMA) including 598 GC primary lesion specimens to investigate the expression of PD-L1 and quantify tumor-infiltrating CD3
+ T lymphocytes, FOXP3 + Tregs, and CD163 + M2 macrophages density to determine their relationships with clinicopathological features and prognosis in GC patients based on different locations, clinicopathological stages, pathological classifications, chemotherapy strategies, and lymph node metastasis. Compared with previous relevant studies, our research have conducted an in-depth analysis of different subgroups of GC, which have rarely been reported before.
Methods

Patients
This study retrospectively evaluated 598 gastric cancer samples from patients who underwent primary tumor resection between June 2005 to December 2015 at the Department of Gastrointestinal Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University. All the samples were definitely diagnosed as gastric cancer by Department of Pathology. We excluded the following types of patients: (1) patients without complete clinical information, postoperative pathological diagnosis, follow-up data, etc.; (2) patients receiving previous radiotherapy or other neoadjuvant treatment; (3) patients with non-neoplastic resection, such as laparotomy or palliative gastrointestinal bypass surgery, and non-adenocarcinoma patients, such as those with gastrointestinal stromal tumors, etc.; (4) patients who suffered from other primary malignant tumors; (5) patients with perioperative death from surgical complications; (6) primary tumor involving ≥ 2 regional sites at the site of occurrence; (7) unclear pathological types; (8) tissue samples were unavailable for TMA. Overall survival time was defined as the interval between gastrectomy and either patient death or the last follow-up. The final follow-up date was June 25, 2018 , for all cases examined [28] [29] [30] .
All patients received standard treatments, such as D2 radical resection and adjuvant chemotherapy according to the NCCN guidelines. The first-line chemotherapy is platinum and fluorouracil. When the patient relapses, the second-line chemotherapy regimen paclitaxel is added. Among them, fluorouracil includes 5-fluorouracil or S-1 (or xeloda); cisplatin includes cisplatin or oxaliplatin; paclitaxel includes paclitaxel and docetaxel.
The patients' tumor staging was in accordance with the American Joint Committee on Cancer (AJCC 8th edition) staging system. For each case, the diagnosis was confirmed by a senior pathologist through a review of H&E-stained slides.
Specimens and quantitative immunohistochemical analysis
The formalin-fixed, paraffin-embedded (FFPE) tissue samples were sliced in consecutive, 5-μm-thick sections. Slides were dewaxed in xylene and rehydrated in graded ethyl alcohol before immunohistochemical staining. Immunohistochemical staining was performed based on the manual of Dako REAL EnVision Detection System (K5007, Dako). The following primary antibodies were used:
Anti-PD-L1 (1:100, 22C3, Dako); Anti-CD163 (1:100, ab87099, Abcam); Anti-CD3 (1:100, ab16669, Abcam); Anti-CD8 (1:100, ab4055, Abcam); and Anti-FOXP3 (1:100, ab20034, Abcam).
In brief, after tissue sections were deparaffinized and rehydrated with graded ethanol, tissues were incubated with 0.3% hydrogen peroxide for 30 min and then blocked with 10% BSA (Sangon, Shanghai, China). Slides were first incubated using the specific antibodies at 4 °C overnight and then labeled with the HRP secondary antibody (Thermo Scientific, US) at room temperature for 1 h. Positive staining was visualized using diaminobenzidin (DAB) substrate liquid (Gene Tech, Shanghai), and counterstained by hematoxylin.
All the staining samples were visualized using the ZEISS Axio Vert.A1 microscope system. For each sample, 5 visual fields showing the highest infiltrating densities at 40× magnification were chosen first, and cell numbers were counted at 200× magnification. After counting the cells, cell destiny was calculated as mm 2 for further statistics. Immune cells in vessels, submucosal lymphatic areas, and necrosis/necrosis adjacent areas were not counted in this research. The positive cell numbers were independently counted, and clinicopathologic data were blinded. In a two-category immunoscore analysis, patients were dichotomized into the high-and low-density group according to the median number of stained cells. As a result, the cutoff for FOXP3 was 11/ mm . PD-L1 positivity was defined as staining in 1% or more tumor cells [31] [32] [33] . PD-L1 expression on tumor cells instead of stroma was immunohistochemically analyzed by an experienced pathologist. Intensity and percentage of stained cells were evaluated separately for tumor and immune cells by 2 individuals who were blinded to the clinicopathological data.
Ethics statement
All experiments were approved by the Ethical Committee of the Shanghai Jiao Tong University School of Medicine, Renji Hospital, and written informed consent was obtained from patients. All procedures followed were by the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients included in the study.
Statistical analyses
SPSS 23.0 and GraphPad Prism 6.0 were used for statistics in this research. Overall survival analysis was performed using the Kaplan-Meier method and the long-rank test. Univariate and multivariate prognostic analyses were performed using the Cox proportional hazards regression model. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated as estimates of the correlations. p-values less than 0.05 were considered statistically significant.
Results
Clinicopathologic characteristics
A total of 598 surgically resected FFPE primary gastric cancer samples in TMA were assessed for FOXP3, CD163, PD-L1, CD3, and CD8 markers, including 418 males and 180 females (Additional file 1: Fig. S1 ). The median overall survival time is 48.1 months (range: 0-123 months), and the median age at diagnosis is 62 years (range: 26-88 years). The tissue samples consist of 14 cases of papillary adenocarcinoma (pap), 183 cases of tubular adenocarcinoma (tub), 316 cases of poor-differentiated adenocarcinoma (por), 22 cases of mucinous adenocarcinoma (muc) and 63 cases of signet ring cell (sig) type (pathological classification by Japanese classification). In total, 124 GC lesions occurred in "the upper parts of the stomach", 197 GC tumors occurred in "the middle parts of the stomach", and 277 GC cases occurred in "the lower parts of the stomach" [6] .
The tumors were classified based on clinical TNM stages, including stage 1 (18.1%), stage 2 (25.1%), stage 3 (44.5%), and stage 4 (12.3%). The 1-, 3-, and 5-year overall survival rates were 1.00, 0.991 ± 0.009, and 0.954 ± 0.023, respectively, for stage 1; 0.927 ± 0.021, 0.827 ± 0.031, and 0.751 ± 0.036, respectively, for stage 2; the rates were 0.838 ± 0.023, 0.444 ± 0.030, and 0.363 ± 0.030, respectively, for stage 3; and the rates were 0.689 ± 0.054,0.132 ± 0.040, and 0.053 ± 0.028, respectively, for stage 4 ( Table 1) .
Regarding all 598 GC patients, univariate survival analysis revealed that age, pathological classification, T stage, N stage, M stage, pathological TNM stage, PD-L1 expression, and CD3, CD8, and CD163 infiltration were all significantly associated with patients prognosis (Additional file 2: Table S1 ). A strong negative correlation was noted between patients' prognosis and the pathological TNM stages. GC patients with positive PD-L1 expression in tumor cells exhibited better survival (5-year OS, 68.4 ± 0.035 vs. 46.3 ± 0.025, p < 0.001). Moreover, CD3 and CD8 also exhibited the same tendency Tables S2, S3, S4) .
At the same time, in the multivariable survival analysis which includes age, pathological classification, T stage, Table S1 ).
Correlation of FOXP3
+ Tregs and CD163 + M2 macrophages
with GC patients' clinicopathological features
In our research, the correlation between FOXP3 + Tregs and patients' prognosis features did not show significant differences among the 598 samples (5-year OS, 51.4 ± 0.029 vs. 55.0 ± 0.029, p = 0.108). However, interestingly, when patients were divided into the earlier stage (stages I-II) and the later stage (stages III-IV), high FOXP3 expression indicates better prognosis (5-year OS, 90.0 ± 0.024 vs. 74.9 ± 0.037 p < 0.001) in the earlier stage group, and FOXP3 + Treg could be an independent favorable prognostic factor in the earlier stage subgroup (HR: 0.207, 95% CI 0.100-0.426, p < 0.001) ( Table 2) .
Nevertheless, in the later stage group, the high expression of FOXP3 indicates poor prognosis (5-year OS, 23.3 ± 0.032 vs. 37.1 ± 0.040 p < 0.001). This phenomenon also indicates that FOXP3 + Treg cells may play a diverse role in the progression of GC (Fig. 1) . CD163 + M2 macrophages could be regarded as an independent poor prognostic factor in all samples (HR: 1.335, 95% CI 1.040-1.715, p = 0.024). M2 macrophages indicated poor prognosis in general. However, high M2 macrophage infiltration suggests a favorable prognosis in signet ring cell carcinoma and mucinous adenocarcinoma (5-year OS, 49.3 ± 0.030 vs 80.3 ± 0.023, p = 0.012) (Additional file 6: Table S5 , Fig. 2e ).
Correlation of CD8
+ lymphocytes, CD3 + lymphocytes and PD-L1 with GC patients' clinicopathological features CD8 + T lymphocytes could be independent favorable prognostic factor in all samples (HR: 0.750, 95% CI 0.573-0.982, p = 0.037). High CD8 expression indicates better prognosis (5-year OS, 58.3 ± 0.029 vs 48.3 ± 0.030, p = 0.009). It could also be an independent favorable prognostic factor in certain subgroups of GC. Nevertheless, CD3 + T lymphocytes are not an independent favorable prognostic factor in the total sample population or any subgroup of GC (Additional files 7, 8: Figs. S3, S4; Table 2 ). In this study, 183 out of 598 cases (30.6%) showed positive PD-L1 expression in tumor cells, whereas 415 patients out of 598 cases (69.4%) showed negative PD-L1 expression in tumor cells. In general, the positive expression of PD-L1 indicates a better prognosis. Positive PD-L1 expression could be an independent favorable prognostic factor in the lymph node metastasis subgroup (HR: 0.621, 95% CI 0.431-0.895, p = 0.011) (Additional file 9: Fig. S2, Table 2 ).
Prognostic value of the combination of FOXP3
+
Tregs, CD163
+
M2 macrophages, and PD-L1 in GC patients
Using two-category immunoscore analysis, combined FOXP3 and CD163, FOXP3 low is an independent favorable prognostic factor in this subgroup (HR: 0.561, 95% CI 0.407-0.774, p < 0.001) and is also an independent favorable prognostic factor in the lymph node metastasis subgroup (HR: 0.654, 95% CI 0.479-0.892, p = 0.007). Nevertheless, FOXP3 high CD163 high is an independent favorable prognostic factor in the signet ring cell and mucinous adenocarcinoma subgroup (HR: 0.154, 95% CI 0.036-0.656, p = 0.011) (Fig. 2f ) . Then, when FOXP3 was combined with PD-L1, FOXP3
high PD-L1 neg could be regarded as a poor prognostic factor in the upper parts subgroup (HR: 2.123, 95% CI 1.309-3.443, p = 0.002) ( Fig. 1e; Table 2 ).
Immune indicators predict different prognosis in stage II-III GC patients treated with different chemotherapy strategies
In this section, we focused on GC patients who are eligible for radical resection. Stage I GC patients did not receive chemotherapy, and stage IV GC patients had distant metastases and were unable to undergo radical resection [34] . Thus, stage II-III GC patients were mainly discussed. First-line chemotherapy for GC is platinum and fluorouracil. When the patient relapses, the secondline chemotherapy regimen paclitaxel is added. Thus, the two main chemotherapy strategies are fluorouracil, cisplatin and paclitaxel (a+b+c) and fluorouracil and cisplatin (a+b). Table S6 ).
Discussion
Immune cells in the tumor microenvironment have a crucial influence on tumor occurrence and development [35] . In this study, we conducted an immunohistochemical evaluation of specific immune indices from 598 GC samples. We mainly focused on specific immune cells and immune indicators that exhibit different prognostic value in different subgroups of GC patients.
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